Rethinking transcription factors and gene expression

Study shows that, like proteins, genomes must fold appropriately to function properly and that some transcription factors provide the structural support.

Nicole Giese Rura | Whitehead Institute
December 7, 2017

Transcription — the reading of a segment of DNA into an RNA template for protein synthesis — is fundamental for nearly all cellular processes, including growth, responding to stimuli, and reproduction. Now, Whitehead Institute researchers have upended our understanding of how transcription is controlled and the role of transcription factors in the process.

The paradigm shift, described in an article online on Dec. 7 in the journal Cell, hinges on a small protein that plays a key role in genome structure and gives us new insights into how changes in the control of transcription and gene expression can lead to disease.

Transcription has several important players that must all be in the right place at the right time: the transcription machinery, transcription factors, promoters, and enhancers.  According to the existing model, transcription factors are proteins that bind to enhancer regions of the genome and recruit the transcription machinery to the promoter DNA regions, which then initiate the genes’ transcription.

“We’ve always assumed that the role of transcription factors was to recruit the transcription machinery to genes to turn them on or turn them off,” says Richard Young, a Whitehead Insistute member and professor of biology at MIT. “But we never imagined that the transcription factors we’ve studied for three decades actually contribute to the genome’s structure. And as a consequence, they regulate genes. So we now look at genomes like proteins: They have to fold up appropriately in order to control genes.”

Scientists have known that the genome’s structure — how it bends and folds — is essential for efficiently compressing two meters of DNA into each human cell, which is the equivalent of packing a strand ten football fields long into a space the size of a marble. Yet until recently, researchers have not had the tools necessary to appreciate this architecture’s importance in fine control of gene expression or study the genome’s structure at sites ready for transcription.

In 2014, Young and his lab determined that portions of the genome reside in loop-based structures, creating insulated neighborhoods that bring enhancers, promoters, and genes into close proximity. Each loop is tied at the top by a pair of molecules, called CTCF, that are bound together. This structure is essential for proper gene control: If the loop structure is broken, gene expression is altered, and cells can become diseased or die.

In the current research, Young along with co-first authors Abraham Weintraub and Charles Li took a closer look at a protein that is well known but not well understood: Yin Yang 1 (YY1). Hundreds of scientific papers have linked YY1 dysfunction to diseases such as viral infections, cancer, and arthritis, and yet the studies produced seemingly contradictory observations of YY1’s function.

According to Young and colleagues, YY1 is a unique transcription factor that occupies both enhancers and promoters, is essential for cell survival, and is found in almost every cell type in humans and mice. Like CTCF, YY1 can also pair with itself and bind to DNA to form loops that enhance DNA transcription.

“YY1 is expressed broadly, and it is necessary for establishing enhancer-promoter loops in multiple cell types,” says Weintraub. “That’s its job, not recruiting the transcription apparatus. When the structure created by YY1 is removed, the genome is no longer folded properly, gene control is lost and transcription of the affected genes is significantly diminished, which can cause dysfunction.”

This model of YY1’s function could account for its association with a number of disparate diseases. Earlier this year, scientists reported YY1 syndrome — a genetic syndrome causing cognitive disabilities in people with mutations in their YY1 gene.

According to Young, YY1 is probably not the only transcription factor with this loop-forming role, and his lab will be searching for additional factors with similar functions.

“YY1 is most likely just the first one, and there are probably a bunch of collaborators that have similar roles,” says Young. “Instead of the classic function that we thought these transcription factors had — interacting with the transcription apparatus and giving instructions on how much or how little of a gene’s transcript to produce — they are bringing together regulatory elements with the gene. The whole job of these transcription factors is just making structure. We are realizing that the things that form physical structures are much more important than we had appreciated.”

The researchers’ work was supported by the National Institutes of Health, the Ludwig Graduate Fellowship funds, the National Science Foundation, the American Cancer Society, a Margaret and Herman Sokol Postdoctoral Award, the Damon Runyon Cancer Research Foundation, and the Cancer Research Institute. The Whitehead Institute has filed a patent application based on this study.

Richard O. Hynes

Education

  • PhD, 1971, MIT
  • MA, 1970, Biochemistry, Cambridge University
  • BA, 1966, Biochemistry, Cambridge University

Research Summary

We study the mechanisms underlying the spread of tumor cells throughout the body, known as metastasis. We are particularly interested in the role of the extracellular matrix — a fibrillar meshwork of proteins that surrounds both normal and tumor cells, which plays many important roles in tumor progression. We also investigate changes in the metastatic cells themselves and in the contributions of normal cells, both in terms of metastasis and other bodily functions.

Awards

  • Paget-Ewing Award, Metastasis Research Society, 2018
  • Inaugural American Society for Cell Biology (ASCB) Fellow, 2016
  • American Association for Cancer Research (AACR) Academy, Fellow, 2014
  • Distinguished Investigator Award, International Society for Matrix Biology, 2012
  • Earl Benditt Award, North American Vascular Biology Organization, 2010
  • Robert and Claire Pasarow Medical Research Award – Cardiovascular, 2008
  • E.B. Wilson Medal, American Society for Cell Biology, 2007
  • President, American Society for Cell Biology, 2000
  • Gairdner Foundation International Award, 1997
  • National Academy of Sciences, Member, 1996
  • National Academy of Medicine, Member, 1995
  • Royal Society of London, Fellow, 1989
  • Howard Hughes Medical Institute, HHMI Investigator, 1988
  • American Association for the Advancement of Science, Fellow, 1987
  • American Academy of Arts and Sciences, Fellow, 1987
  • John Simon Guggenheim Memorial Foundation, Guggenheim Fellowship, 1982

Media Inquiries

For media inquiries, please email rhynes-admin@mit.edu.

Laurie A. Boyer

Education

  • PhD, 2001, University of Massachusetts Medical School
  • BS, 1990, Biomedical Science, Framingham State University

Research Summary

We investigate how complex circuits of genes are regulated to produce robust developmental outcomes particularly during heart development. A main focus is to determine how DNA is packaged into chromatin, and how ATP-dependent chromatin remodelers modify this packaging to control lineage commitment. We are now applying these principles to develop methods to stimulate repair of damaged cardiac tissue (e.g., regeneration). Our ability to combine genomic, genetic, biochemical, and cell biological approaches both in vitro and in vivo as well as ongoing efforts to use tissue engineering to model the 3D architecture of the heart will ultimately allow us to gain a systems level and quantitative understanding of the regulatory circuits that promote normal heart development and how faulty regulation can lead to disease.

Learn More

Awards

  • Medicine by Design Distinguished Lecture, 2017
  • Cardiovascular Rising Star Distinguished Lecture, 2017
  • American Heart Association Innovative Research Award, 2013
  • Irvin and Helen Sizer Career Development Award, 2012
  • Smith Family Award for Excellence in Biomedical Science, 2009
  • Massachusetts Life Sciences Center New Investigator Award, 2008
  • Pew Scholars Award in the Biomedical Sciences, 2008
  • Honorary Doctorate, Framingham State College, 2007
  • The Scientific American World’s 50 Top Leaders in Research, Business or Policy, 2006
Robert A. Weinberg

Education

  • PhD, 1969, MIT
  • SB, 1964, Biology, MIT

Research Summary

We investigate three broad questions related to the origin and spread of cancer. First, how do cancer cells within a primary tumor acquire the ability to invade and metastasize? Second, how are the stem-cell state and the epithelial-mesenchymal transition interrelated? Third, how are the regulators of the epithelial-mesenchymal transition able to activate this profound change in cell phenotype?

Awards

  • Japan Prize, Japan Prize Foundation, 2021
  • Salk Institute Medal for Research Excellence, 2016
  • Breakthrough Prize in Life Sciences, 2013
  • Wolf Foundation Prize, 2004
  • Institute of Medicine, Member, 2000
  • Keio Medical Science Foundation Prize, 1997
  • National Science Foundation, National Medal of Science, 1997
  • Harvey Prize, 1994
  • American Academy of Arts and Sciences, Fellow, 1987
  • Sloan Prize, GM Cancer Research Foundation, 1987
  • National Academy of Sciences, Member, 1985
  • Robert Koch Foundation Prize, 1983
Omer H. Yilmaz

Education

  • PhD, 2008, University of Michigan; MD, 2008, University of Michigan Medical School
  • BS, 1999, Biochemistry and Physics, University of Michigan

Research Summary

The adult intestine is maintained by stem cells that require a cellular neighborhood, or niche, consisting in part of Paneth cells. Our laboratory will investigate the molecular mechanisms of how intestinal stem cells and their Paneth cell niche respond to diverse diets to coordinate intestinal regeneration with organismal physiology and its impact on the formation and growth of intestinal cancers.  By better understanding how intestinal stem cells adapt to diverse diets, we hope to identify and develop new strategies that prevent and reduce the growth of cancers involving the intestinal tract that includes the small intestine, colon, and rectum.

Awards

  • AAAS Martin and Rose Wachtel Cancer Research Award, 2018
  • Pew-Stewart Trust Scholar, 2016-2020
  • Sidney Kimmel Scholar, 2016-2020
  • V Foundation Scholar, 2014-2017
  • Harold M. Weintraub Award, 2007
H. Robert Horvitz

Education

  • PhD, 1974, Harvard University
  • BS, 1968, Mathematics and Economics, MIT

Research Summary

Our lab examines how genes control animal development and behavior. We use the experimentally tractable nematode Caenorhabditis elegans to identify and analyze molecular and cellular pathways involved in these important areas of biology. Ultimately, we hope to clarify these fundamental biological mechanisms and provide further insight into human disease.

Awards

  • U.S. National Academy of Inventors, Member, 2015
  • American Association for Cancer Research Academy, Fellow, 2013
  • Royal Society of London, Foreign Member, 2009
  • Genetics Society (U.K.), Mendel Medal, 2007
  • Eli Lilly Lecturer Award, 2007
  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2006
  • National Academy of Medicine, Member, 2003
  • American Cancer Society, Medal of Honor, 2002
  • The Nobel Foundation, Nobel Prize in Physiology or Medicine, 2002
  • Bristol-Myers Squibb, Award for Distinguished Achievement in Neuroscience, 2001
  • March of Dimes, Developmental Biology, 2000
  • Gairdner Foundation, Gairdner Foundation International Award, 1999
  • National Academy of Sciences, Member, 1991
  • American Academy of Arts and Sciences, Fellow, 1989
  • American Association for the Advancement of Science, Fellow, 1989
  • Howard Hughes Medical Institute, HHMI Investigator, 1988
Peter Reddien

Education

  • PhD, 2002, MIT
  • SB, 1996, Molecular Biology, University of Texas at Austin

Research Summary

We investigate how stem cells are regulated to regenerate missing tissues. We study the cellular events involved in this process and the attendant roles for regulatory genes that control regeneration steps. We utilize an array of methodologies, including high-throughput sequencing, RNA interference (RNAi) screening, and numerous assays and tools for phenotypic analysis to characterize regeneration regulatory genes.

Awards

  • Howard Hughes Medical Institute, HHMI Investigator, 2013
Richard A. Young

Education

  • PhD, 1979, Yale University
  • BS, 1975, Biological Sciences, Indiana University

Research Summary

We use experimental and computational technologies to determine how signaling pathways, transcription factors, chromatin regulators and small RNAs regulate gene expression in healthy and diseased cells. Our interests range from the basic molecular mechanisms behind gene control to drug development for cancer and other diseases caused by gene misregulation.

Awards

  • National Academy of Medicine, Member, 2019
  • National Academy of Sciences, Member, 2012
Adam C. Martin

Education

  • PhD, 2006, University of California, Berkeley
  • BS, 2000, Biology and Genetics, Cornell University

Research Summary

We study how cells and tissues change shape during embryonic development, giving rise to different body parts. We visualize these changes to determine how mechanical forces drive massive tissue movements in the fruit fly, Drosophila melanogaster. In addition, we also study the regulation of tissue integrity, investigating the processes that regulate the epithelial-to-mesenchymal transition or EMT.

Eliezer Calo

Education

  • PhD, 2011, MIT
  • BS, 2006, Chemistry, University of Puerto Rico-Río Piedras

Research Summary

We focus on the molecular entities controlling and coordinating RNA metabolism — that is, the compendium of processes that involve RNA, including protein synthesis, processing, modifications, export, translation and degradation. Our goal is to understand how different aspects of RNA metabolism are controlled to generate structure and function during development, as well as how mutations in components of the RNA metabolic program lead to congenital disorders and cancer.